Tofacitinib

Overview

Tofacitinib, sold under the brand Xeljanz, Neojanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular-course juvenile idiopathic arthritis, and ulcerative colitis. It is a janus kinase (JAK) inhibitor, discovered and developed by the National Institutes of Health and Pfizer.[1][2][3] WP

Common side effects include diarrhea, headache, and high blood pressure. Serious side effects may include infections, cancer, and pulmonary embolism. In 2019, the safety committee of the European Medicines Agency began a review of tofacitinib and recommended that doctors temporarily not prescribe the 10 mg twice-daily dose to people at high risk for pulmonary embolism. The U.S. Food and Drug Administration (FDA) also released warnings about the risk of blood clots. An important side effect of Jakinibs is serious bacterial, mycobacterial, fungal and viral infections. In the phase III trials of tofacitinib among opportunistic infections, pulmonary tuberculosis (TB) was reported in 3 cases all of which were initially negative upon screening for TB.[3–9] WP

It was approved for medical use in the United States in November 2012. The extended-release version was approved in February 2016. It is available as a generic medication.[10][11][12] WP

Uses, dosage and effects

Rheumatoid arthritis

Tofacitinib citrate is approved for medical use in the United States with an indication "to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate".[1][13] WP

In the European Union, in combination with methotrexate, tofacitinib citrate is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs. It can be given as monotherapy in case of intolerance to methotrexate or when treatment with MTX is inappropriate.[2] WP

Ulcerative colitis

In May 2018, the FDA approved tofacitinib citrate "for the treatment of adult patients in the U.S. with moderately to severely active ulcerative colitis." Tofacitinib citrate is the first oral JAK inhibitor approved for use in chronic ulcerative colitis.[14] WP

Risks and side effects

Adverse effects

Tofacitinib was initially not approved by European regulatory agencies because of concerns over efficacy and safety, although by 2018, the European Commission had approved it. Animal studies with tofacitinib conducted prior to human trials showed some carcinogenesis, mutagenesis, and impairment of fertility.[1][15][16] WP

The most commonly reported adverse reactions during the first three months in controlled clinical trials (occurring in 2% or more of patients treated with tofacitinib citrate monotherapy or in combination with DMARDs) were upper respiratory tract infections, headache, diarrhea, and nasopharyngitis (the "common cold").[1] WP

Tofacitinib is required by the FDA to have a boxed warning on its label about possible injury and death due to problems such as infections, lymphoma, and other malignancies, which can arise from use of this drug. Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving tofacitinib. Epstein Barr virus-associated post-transplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with tofacitinib while on immunosuppressive medications. Patients are warned to avoid use of tofacitinib citrate during an "active serious infection, including localized infections". Doctors are advised to use it with caution in patients who may be at increased risk of gastrointestinal perforations. Laboratory monitoring is recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids. Tofacitinib claims to have no contraindications, but doctors are advised to reduce the patient's dosage when combined with "potent inhibitors of cytochrome P450 3A4 (CYP3A4)," such as ketoconazole, or one or more combined medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 such as fluconazole. Furthermore, immunizations with live vaccines should be avoided by tofacitinib users.[1][13] WP

According to postmarketing research, tofacitinib may also increase the risk for pulmonary embolism. Prescribers should consider risk factors for pulmonary embolism, including age, obesity, smoking, and immobilization before prescribing this medication. Patients taking this medication, irrespective of indication or risk factors, should be monitored for signs and symptoms of pulmonary embolism.[17] WP

Pharmacology

Mechanism

It is an inhibitor of the enzyme janus kinase 1 (JAK1) and janus kinase 3 (JAK 3), which means that it interferes with the JAK-STAT signaling pathway, which transmits extracellular information into the cell nucleus, influencing DNA transcription.[18] WP

In a mouse model of established arthritis, tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue. This efficacy in this disease model correlated with the inhibition of both JAK1 and JAK3 signaling pathways, suggesting that tofacitinib may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.[19] WP

Research

Research

It has demonstrated effectiveness in the treatment of psoriasis in phase III studies. As of November 2013 it was studied in immunological diseases, as well as for the prevention of organ transplant rejection.[20–23] WP

Psoriasis

Tofacitinib is an investigational drug in psoriasis. As of October 2015, it demonstrated its effectiveness for plaque psoriasis in phase III, randomized, controlled trials in comparison to placebo and to etanercept. In particular, a ten-mg, twice-daily dose of tofacitinib was shown to be not inferior to etanercept 50 mg, subcutaneously, twice weekly. In October 2015, the FDA rejected approval of tofacitinib for the treatment of psoriasis due to safety concerns.[24–28] WP

Alopecia areata

Based on preclinical studies in a mouse model of the disease, tofacitinib has been investigated for the treatment of alopecia areata. Early case reports suggested potential efficacy, as did a phase II open-label clinical trial, published in tandem with a phase II clinical trial showing the same for ruxolitinib.[29–33] WP

Vitiligo

In a June 2015 case report, a 53-year-old woman with vitiligo showed noticeable improvement after taking tofacitinib for five months.[34] WP

Atopic dermatitis

The results of using tofacitinib in six patients with recalcitrant atopic dermatitis was published in September 2015. All saw improvement in their atopic dermatitis without any adverse events.[35] WP

Ankylosing spondylitis

In 2021 and 2022, results of a phase III randomised, double-blind, placebo-controlled trial were reported, that showed significant improvements for patients with active ankylosing spondylitis compared to placebo.[36][37] WP

Ulcerative colitis

As of November 2013, it was studied for treatment of inflammatory bowel disease.The FDA approved tofacitinib in May 2018 for treatment of ulcerative colitis.[14][27][38] WP

Epilepsy

Tofacitinib has been investigated in several preclinical mouse models of epilepsy, since the JAK/STAT pathway is hyperactive following the onset of epilepsy in rodent models. Giving the drug to mice with chronic-phase epilepsy reduced seizures and restored cognitive function for up to 2 months following a course of the drug treatment.[39][40] WP

History

History

The potential significance of JAK3 inhibition was first discovered in the laboratory of John O'Shea, an immunologist at the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH). In 1994, Pfizer was approached by the NIH to form a public-private partnership to evaluate and bring to market experimental compounds based on this research. Pfizer initially declined the partnership, but agreed in 1996, after the elimination of an NIH policy dictating that the market price of a product resulting from such a partnership would need to be commensurate with the investment of public taxpayer revenue and the "health and safety needs of the public". Pfizer worked with O'Shea's laboratory to define the structure and function of JAK3 and its receptors, and then handled the drug discovery, preclinical development, and clinical development of tofacitinib in-house.[41][42] WP

The drug was coded as CP-690,550 during development. Its original recommended International nonproprietary name (rINN) was tasocitinib, but that was overruled during the INN approval process as being not optimally differentiable from other existing INNs, so the name "tofacitinib" was proposed and became the INN.[43][44] WP

In November 2012, the FDA approved tofacitinib for treatment of rheumatoid arthritis.[1][10] WP

A 2014 study showed that tofacitinib treatment was able to convert white fat tissues into more metabolically active brown fat, suggesting it may have potential applications in the treatment of obesity.[45] WP

In November 2012, the FDA approved tofacitinib to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate. The FDA approved only the five-mg, twice-daily dose on the grounds that a higher dose was not considered to have an adequate risk-to-benefit ratio.[13][24] WP

In September 2020, the FDA approved tofacitinib for the treatment of children and adolescents two years of age and older with active polyarticular course juvenile idiopathic arthritis.[46] WP

In December 2021, the FDA approved tofacitinib for the treatment of adults with active ankylosing spondylitis.[47] WP

As of June 2021, tofacitinib is available as a generic medicine in the US.[48][49] WP

Legal status

Economics

Pfizer reported revenue of US$1.703 billion for Xeljanz in 2023. In 2023, the Institute for Clinical and Economic Review (ICER) identified Xeljanz as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Xeljanz's wholesale acquisition cost rose by 6%, leading to an additional $72 million in costs to U.S. payers.[50][51] WP

Names

Tofacitinib is marketed as Xeljanz except for Russia, where it is marketed as Jaquinus.[52] WP

Chemistry

Formula

C16H20N6O PC

CAS number

477600-75-2 PC

Molar mass (g/mol)

312.37 PC

IUPAC name (computed by PubChem)

3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile PC

SMILES

C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N PC

InChIKey

UJLAWZDWDVHWOW-YPMHNXCESA-N PC

PubChem CID

9926791

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Xeljanz- tofacitinib tablet, film coated Xeljanz XR- tofacitinib tablet, film coated, extended release Xeljanz- tofacitinib solution. 2 October 2020
2. Journal / agency Xeljanz EPAR. 17 September 2018
3. Other Tofacitinib Citrate
4. Journal / agency Safety Alerts for Human Medical Products - Xeljanz, Xeljanz XR (tofacitinib): Safety Communication - Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients
5. Journal / agency Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019, May 17, 2019. 17 May 2019
6. Journal / agency Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication - Due to an Increased Risk of Blood Clots and Death with Higher Dose. 26 July 2019
7. Journal / agency FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). 5 August 2019
8. Journal / agency FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). 15 December 2019
9. Journal / agency O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Annals of the Rheumatic Diseases. April 2013. doi:10.1136/annrheumdis-2012-202576 · PMID 23532440 · PMC3616338
10. Journal / agency Drug Approval Package: Xeljanz (tofacitinib) Tablets NDA #203214. 28 December 2012
11. Journal / agency Drug Approval Package: Xeljanz (tofacitinib) Extended Release (XR) Tablets NDA #208246. 26 June 2017
12. Journal / agency First Generic Drug Approvals 2023. 30 May 2023
13. Journal / agency FDA approves Xeljanz for rheumatoid arthritis. 6 November 2012
14. Journal / agency FDA approves new treatment for moderately to severely active ulcerative colitis. 30 May 2018
15. Other Nordqvist C. Pfizer's Arthritis Drug Xeljanz (tofacitinib) Receives A Negative Opinion In Europe. 27 April 2013
16. Other McKee S. EU approves Pfizer's Xeljanz for psoriatic arthritis. 29 June 2018
17. Other FDA Warns of Risk for PE, Death With Higher Dose Tofacitinib (Xeljanz) for RA - Medscape - 25 February 2019
18. Journal / agency Adis Editorial. Tofacitinib. Drugs in R&D. 2010. doi:10.2165/11588080-000000000-00000 · PMID 21171673 · PMC3585773
19. Journal / agency Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). Journal of Immunology. April 2011. doi:10.4049/jimmunol.1003668 · PMID 21383241 · PMC3108067
20. Other Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Pearson TC, Webber SA. Textbook of Organ Transplantation Set. 21 July 2014
21. Journal / agency Wojciechowski D, Vincenti F. Tofacitinib in kidney transplantation. Expert Opinion on Investigational Drugs. September 2013. doi:10.1517/13543784.2013.811231 · PMID 23841583
22. Journal / agency Myrvang H. Transplantation: Tofacitinib safe and effective in renal transplant recipients. Nature Reviews. Nephrology. June 2012. doi:10.1038/nrneph.2012.120 · PMID 22735765
23. Journal / agency Kalluri HV, Hardinger KL. Current state of renal transplant immunosuppression: Present and future. World Journal of Transplantation. August 2012. doi:10.5500/WJT.v2.i4.51 · PMID 24175197 · PMC3782235
24. Journal / agency Di Lernia V, Bardazzi F. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. Drug Design, Development and Therapy. January 2016. doi:10.2147/DDDT.S82599 · PMID 26889081 · PMC4743637
25. Journal / agency Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. The British Journal of Dermatology. October 2015. doi:10.1111/bjd.14018 · PMID 26149717
26. Journal / agency Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. August 2015. doi:10.1016/S0140-6736(14)62113-9 · PMID 26051365
27. Journal / agency Zand MS. Tofacitinab in renal transplantation. Transplantation Reviews. July 2013. doi:10.1016/j.trre.2013.04.001 · PMID 23849222 · PMC3713609
28. Other Pfizer Receives Complete Response Letter from FDA for Oral Xeljanz (tofacitinib citrate) Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis. 14 October 2015
29. Journal / agency Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nature Medicine. September 2014. doi:10.1038/nm.3645 · PMID 25129481 · PMC4362521
30. Journal / agency Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. The Journal of Investigative Dermatology. December 2014. doi:10.1038/jid.2014.260 · PMID 24940651
31. Journal / agency Jabbari A, Nguyen N, Cerise JE, Ulerio G, de Jong A, Clynes R, Christiano AM, Mackay-Wiggan J. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Experimental Dermatology. August 2016. doi:10.1111/exd.13060 · PMID 27119625 · PMC4963264
32. Journal / agency Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC, Marinkovich MP, Christiano AM, Oro AE, King BA. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. September 2016. doi:10.1172/jci.insight.89776 · PMID 27699252 · PMC5033755
33. Journal / agency Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. September 2016. doi:10.1172/jci.insight.89790 · PMID 27699253 · PMC5033756
34. Journal / agency Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatology. October 2015. doi:10.1001/jamadermatol.2015.1520 · PMID 26107994
35. Journal / agency Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. Journal of the American Academy of Dermatology. September 2015. doi:10.1016/j.jaad.2015.06.045 · PMID 26194706
36. Journal / agency Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O, Fallon L, Kanik KS, van der Heijde D. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. August 2021. doi:10.1136/annrheumdis-2020-219601 · PMID 33906853 · PMC8292568
37. Journal / agency Navarro-Compán V, Wei JC, Van den Bosch F, Magrey M, Wang L, Fleishaker D, Cappelleri JC, Wang C, Wu J, Dina O, Fallon L, Strand V. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. June 2022. doi:10.1136/rmdopen-2022-002253 · PMID 35654457 · PMC9163535
38. Journal / agency Vuitton L, Koch S, Peyrin-Biroulet L. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. Current Drug Targets. November 2013. doi:10.2174/13894501113149990160 · PMID 23627915
39. Journal / agency Hoffman OR, Koehler JL, Espina JE, Patterson AM, Gohar ES, Coleman EM, Schoenike BA, Espinosa-Garcia C, Paredes F, Varvel NH, Dingledine RJ, Maguire JL, Roopra AS. Disease modification upon 2 weeks of tofacitinib treatment in a mouse model of chronic epilepsy. Science Translational Medicine. March 2025. doi:10.1126/scitranslmed.adt0527 · PMID 40106581
40. Other Could an arthritis drug unlock lasting relief from epilepsy and seizures? UW–Madison researchers see promising results in mice
41. Other Weisman J. Seeking Profit for Taxpayers in Potential of New Drug. 18 March 2013
42. Journal / agency Garber K. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nature Biotechnology. January 2013. doi:10.1038/nbt0113-3 · PMID 23302910
43. Journal / agency Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis and Rheumatism. July 2009. doi:10.1002/art.24567 · PMID 19565475
44. Other Herper M. Why Pfizer's Biggest Experimental Drug Got A Name Change. 2 March 2011
45. Journal / agency Moisan A, Lee YK, Zhang JD, Hudak CS, Meyer CA, Prummer M, Zoffmann S, Truong HH, Ebeling M, Kiialainen A, Gérard R, Xia F, Schinzel RT, Amrein KE, Cowan CA. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nature Cell Biology. January 2015. doi:10.1038/ncb3075 · PMID 25487280 · PMC4276482
46. Other U.S. FDA Approves Pfizer's Xeljanz (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
47. Other U.S. FDA Approves Pfizer's Xeljanz (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
48. Journal / agency Tofacitinib citrate: FDA-Approved Drugs
49. Journal / agency Tofacitinib: FDA-Approved Drugs
50. Other Pfizer's year in review. 31 December 2023
51. Other Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US
52. Other Pfizer Provides Update on Global Regulatory Approvals and Launches of Xeljanz (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis. 15 July 2013

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.